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SUMMARY 
Different clinical response of different patients to the 
same medicine has been recognised and documented 
since the 1950’s. Variability in response of individuals 
to standard doses of drug therapy is important in clini-
cal practice and can lead to therapeutic failures or ad-
verse drug reactions. Pharmacogenetics seeks to identi-
fy individual genetic differences (polymorphisms) in 
drug absorption, metabolism, distribution and excretion 
that can affect the activity of a particular drug with the 
view of improving efficacy and reducing toxicity. Alt-
hough knowledge of pharmacogenetics is being trans-
lated into clinical practice in the developed world, its 
applicability in the developing countries is low. Several 
factors account for this including the fact that there is 
very little pharmacogenetic information available in 
many indigenous African populations including Ghana-
ians. A number of genes including Cytochrome P450 
(CYP) 2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, 
CYP2D6, MDR1 and TPMT have been genotyped in 
the Ghanaian population since the completion of the 
Human genome project. There is however, an urgent 
need to increase pharmacogenetic research in Ghana to 
increase availability of data. Introducing Pharmaco-
genetics into the curriculum of Medical and Pharmacy 
training institutions will influence translating 
knowledge of pharmacogenetics into clinical practice. 
This will also equip health professionals with the skill 
to integrate genetic information into public health deci-
sion making.   
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INTRODUCTION 
Different clinical response of different people to the 
same medicine has been recognised and documented 
since the 1950’s with the observation of variable inher-
ited clinical responses to drugs such as primaquine and 
isoniazid.1 A drug may not be effective in some pa-
tients but may be more pharmacologically active or 
even toxic in other patients. This wide variability in the 
response of individuals to standard doses of drug ther-
apy is an important problem in clinical practice where 
it can lead to therapeutic failures or adverse drug reac-
tions (ADRs). In addition to non-genetic factors such 
as age, organ function, associated therapy and the na-
ture of the disease causing variability in the effects of 
the medications, in many patients, genetic factors have 
been established to influence the use of medicines be-
tween individuals and remain stable throughout the life 
time of the patient. Recent research on drug metabolis-
ing enzymes (DMEs), drug transporters and drug re-
ceptors in relation to individual clinical response to the 
same drug dosage gave rise to the field of pharmaco-
genetics. Pharmacogenetics aims to identify polymor-
phisms in the genes that can affect the usefulness or 
efficacy of a particular drug, thereby increasing the 
number of patients responding to the drug and decreas-
ing the number of individuals affected by ADRs. The 
ultimate aim of pharmacogenetics is to achieve indi-
vidualised or tailored therapy. In addition to estab-
lished medical practice of individualising medication 
doses based on renal or liver function, individualised or 
personalised medicine involves the use of both pa-
tient’s genetic data and phenotypic information to 
choose therapy that will best maximise the efficacy of 
the drug and minimise adverse events.2 Traditionally, 
two main methods have been used to determine the 
appropriate drug therapy for patients. The initial meth-
od is based on trial and error, where different first-line 
drugs are given until the most effective treatment is 
found. The second method is based on diagnoses; pa-
tients with the same disease receive the same treatment 
in a sort of “one size fits all” approach.3 Despite im-
provements of this second approach over the trial and 
error, it is still fraught with challenges. Individualised 
therapy therefore seeks to minimise the problems asso-
ciated with the “one size fits all” approach to drug 








Although pharmacogenetics emerged several decades 
ago, only recently have the tools been in place for the 
field to flourish, partly led by the decoding of the hu-
man genome sequence and improving genotyping 
technologies. 
The most common genetic variations within the human 
genome are single nucleotide polymorphisms (SNPs) 
accounting for nearly 90% of all these variations. SNPs 
play clinically important roles in enzyme activity and 
have been shown to either increase or decrease metabo-
lism of many drugs. Variation in genes occurring in at 
least 1% of the population is termed as polymorphism.4 
Relevant polymorphisms associated with drug effects 
occur in genes encoding enzymes and transporters re-
sponsible for absorption, distribution, metabolism and 
excretion (ADME).5   
 
DRUG DISPOSITION AND 
PHARMACOGENETICS 
Drug Metabolism 
Drug metabolism takes place in two phases classified 
as either phase I or phase II. Majority of enzymes in-
volved in phase I metabolism belong to a large cyto-
chrome P450 (CYP) family of drug metabolising en-
zymes that catalyse hydrolysis, reduction and oxidation 
reactions.6 CYP is made up of 18 families which are 
divided into 44 subfamilies consisting of 57 genes.2 
CYP1, CYP2 and CYP3 families control the metabo-
lism of most drugs. At least 75% of prescribed drugs 
on the market are metabolised by CYP3A, CYP2D6 
and CYP2C.7 Phase II enzymes are involved in reac-
tions such as sulfation, acetylation conjugation and 
glucuronidation which may lead to the excretion of 
drugs by increasing the hydrophilicity of the substrate 
or deactivation of highly reactive substrates.6 N-
acetayltransferases 1 and 2 (NAT1 and NAT2), thiopu-
rine S-methyltranferases (TPMT) and Uridine 
disphospahate glucoronosyltransferases (UGT) are the 
main phase II enzymes.  
 
Drug Transporters 
Drug transporters do play an important role in drug 
uptake, bioavailability, efficacy, toxicity and clear-
ance.8 Many drugs can be passively diffused across 
membranes, however, some have to be actively trans-
ported either by efflux and/or influx mechanism or 
through facilitated diffusion. There are two main types 
of transporters that affect ADME of drugs. These are 
the ATP-binding cassette (ABC) proteins and solute-
linked carrier (SLC) proteins. Whereas the ABC trans-
porters are efflux proteins,8 the SLC proteins are influx 
transporters.9 These drug transporters generally a have 
broad range of substrates and understanding genetic 
variations within the transporter genes is important for 
individualising therapy.  
Drug Targets 
Polymorphisms sometimes occur in drug targets and 
nuclear receptors which may not be directly involved 
in drug metabolism or transport but may be of equal 
pharmacogenomic importance because they may affect 
the patient’s response to treatment. For example, SNPs 
found in epidermal growth factor receptor (EGFR) has 
been associated with better survival rates in patients 
with colorectal cancer and treated with irinotecan and 
cetuximab; which are anti epidermal growth factor 
receptor antibodies.10 It is also known that pregnane X 
receptor (PXR), which is a nuclear receptor regulates 
the expression of many ADME genes, and therefore 
plays an important role in drug response.11  The list of 
SNPs found in gene encoding drug metabolising en-
zymes, drug transporters and targets are growing. And 
these polymorphisms have been associated with drug 
effects in humans.5  
 
Interethnic variations 
Many clinically relevant polymorphisms have been 
demonstrated to vary between different populations.12-
14  For example, significant differences have been re-
ported for CYP2C9*2 and CYP2C9*3 variant alleles at 
3.3% and 2.3% respectively in African American popu-
lations.15 In contrast, the CYP2C9*2 variant allele was 
reported at 8-19% and the CYP2C9*3 variant allele at 
3.3-17% for populations defined as Caucasian.13 
CYP2C9*2 variant allele was rarely seen in Asian pop-
ulations while the CYP2C9*3 variant allele was preva-
lent at 1.1-6.8% within the Asian populations.13  Avail-
able data also suggests differences within defined eth-
nic groups.16 For example, glutathione S-transferases 
(GST) which have been implicated in resistance of 
many anticancer agents have significantly lower fre-
quencies for Tanzanian (0.16), South African (0.14), 
and Zimbabwean (0.24) as compared with Ghanaian 





There are many actual and potentially useful applica-
tions of pharmacogenetic. In the US, the Food and 
Drug Administration (FDA) has started adding phar-
macogenetics information into prescribing information 
for a number of drugs including warfarin, carbamaze-
pine and codeine, to assist prescribers achieve safe and 
rapid therapeutic doses.18 
 
Pharmacogenetics testing 
Glucose-6-phosphate dehydrogenase (G6PD) deficien-
cy is one of the pharmacogenetic tests that have been 
accepted as routine tests for a long time.  
 
 





Patients with G6PD deficiency are at risk of haemoly-
sis following the intake of certain medicines. Tradi-
tional laboratory tests and therapeutic drug monitoring 
assess the effects of these medicines.  
 
Over the last 15 years, there has been an increase in the 
use of predictive genetic testing before prescribing 
some medicines. This testing has been recommended 
by the United States FDA, although this is not manda-
tory. These tests can help Clinicians and Pharmacists 
identify potential responders and/or non responders 
before treatment is started.  The testing of SNPs of 
CYP2C9 and vitamin K epoxide reductase complex 
subunit 1 (VKORC1) is recommended before prescrib-
ing warfarin, a blood thinning agent. CYP2C9*2 which 
is a C to T mutation at position 430 results in 30% to 
40% reduction in enzymatic activity of warfarin while 
VKORC1 is the site of action for warfarin and a G to A 
mutation at position -1639 within the promoter region 
of this gene has been associated with reduced enzyme 
activity. Patients with a combination of these variants 
may lead to a ‘low dose’ phenotype.  Patients carrying 
the ‘A’ allele will require lower doses of warfarin to 
achieve therapeutic anti coagulation and avoid severe 
adverse reactions.19  
 
Recent evaluation of a cohort of approximately 1500 
Swedish patients confirmed that SNPs in VKORC1 and 
CYP2C9 can predict approximately 40% of dose vari-
ance, while non-genetic factors (age, sex, body mass 
index etc) jointly account for nearly 15%.20 The use of 
this genetic information together with other clinical 
information is useful in determining the correct start 
dose of warfarin in patients. 
 
Also in the US, prescribing guidance for drugs such as 
imatinib (Gleevec®) and trastuzumab (Herceptin®)  
now includes information on the use of predictive ge-
netic tests that can assist prescribers to identify poten-
tial responders or those who are likely to develop 
ADRs. Trastuzumab is a drug designed to target an 
abnormal protein, HER2, which makes tumors grow. A 
third of breast cancers have a mutation in the gene that 
causes high HER2 levels. Patients with breast cancer 
that test positive for this mutation are likely to respond 
well to trastuzumab, shrinking the tumors, slowing 
down the disease progression and increasing  survival.  
 
Pharmacogenetics testing has increased over the years 
in UK. There is a routine testing for TPMT before pre-
scribing thiopurine drugs such as Mercaptopurine and 
Azathiopurine in leukemia treatment. Patients with 
weakened version of TMPT cannot receive the regular 
dosage of the thiopurine drugs which interfere with 
DNA replication in rapidly dividing cells.  
TPMT deficiency patients need to be identified to pre-
vent severe to fatal homological toxicity.  
 
HLA-B*5701 genotyping is also recommended before 
the use of Abacavir to prevent drug related hypersensi-
tivity. HLA-B*5701 testing before Abacavir use has 
been shown to be feasible, cost effective and saves 
lives.21 Pharmacogenetics tests are now being used to 
supplement traditionally established diagnostic meas-
urement of biomarkers in the blood to assist with dose 
determination and choice of medication. Clinical bene-
fits of pharmacogenetics testing depend on the illness, 
treatment goals, cost and benefits.  
 
Pharmacogenetics has the potential of facilitating drug 
discovery and allowing drug manufacturers to produce 
a therapy targeted at specific diseases using genome 
targets. Previously failed drugs can also be revived as 
they are matched with subgroup of patients with specif-
ic polymorphisms. 
 
Whereas pharmacogenetics is being used in the devel-
oped world, the same cannot be said of Africa includ-
ing Ghana. There is a fair amount of genotype data 
from published literature on the Ghanaian population 
compared to other African countries (Tables 1). This 
review seeks to examine these studies and their poten-
tial implications for drug therapy in Ghana. 
 
PHARMACOGENETICS IN GHANA 
Over the past decade, a significant amount of phar-
macogenetic research has been carried out on the Gha-
naian population by various research groups. The genes 
of interest for these researchers were based on their 
involvement in ADME of essential drugs. These genes 
have been listed in Table 1 and Table 2.  
 
Interest in the area of pharmacogenetics in Ghana start-
ed with a study on the metabolism of pro- drugs Spar-
teine and Debrisoquine. The authors observed pro-
nounced differences in the metabolism of these drugs 
between African and Caucasian populations.22, 23  This 
observation of higher metabolic ratio values among 
Africans was attributed to mutations within the 
CYP2D6 gene. CYP2D6*17 allele which encodes the 
enzyme with lower catalytic function.24 was found at a 
frequency of 26% among Ghanaian population.25 The 
authors also observed the existence of other variants of 
CYP2D6*1 allele among Ghanaians which also en-
codes CYP2D6 enzymes with reduced catalytic capaci-
ty compared to Caucasian.25 CYP2D6 enzymes are 
involved in the metabolism of several drugs and de-
crease expression of this enzyme may have implica-
tions for use of drugs such as chlorpromazine, codeine, 
fluoxetine, imipramine morphine, propranolol and ta-
 
 




moxifen found in Standard treatment guidelines (STG) 
and the essential medicines list (EML) of Ghana. 
 
Other enzymes of pharmacogenetic importance have 
also been studied among Ghanaians. These include 
CYP3A4/5, CYP2C8, CYP2A6, CYP2B6, CYP2C9 
CYP2C19 and CYP2D6. CYP3A4/5 enzymes have 
been reported to be expressed with high inter individu-
al variability.26 CYP3A4*1B variant, associated with a 
decrease in enzymatic activity of CYP3A4 gene, has 
been reported between 69% and 82% among Ghana-
ians (Table 1). CYP3A4*1B variant has also been asso-
ciated with various diseases such as breast and prostate 
cancer.27, treatment related leukaemia.28 Men who are 
homozygote carriers of the CYP3A4*1B variant are at 
more significant risk of prostate cancer at a higher 
stage and grade.27, 28 
 
Table 1: Allele frequencies of Phase I genes in Ghana-
ian population 
Gene Allele No Variant Reference 


































































































































*6 95 0.16 
 
CYP2C8*2 and CYP2C8*3 variants have been associ-
ated with reduced enzymatic activity. However, only 
the CYP2C8*2 variant has been reported in all the stud-
ies in Ghana (Table 1). CYP2C8*2 variant may have 
the potential implication for the metabolism of a num-
ber of therapeutic agents, such as amodiaquine, dap-
sone, ibuprofen and morphine on the GEML. 
CYP2C8*2 variant has been associated with a decrease 
in enzymatic activity which leaves more Amodiaquine 
to turn into a toxic metabolite. These metabolites can 
cause leucopenia and liver toxicities as side effects.  
 
Table 2: Allele frequencies of Phase II genes in Ghana-
ian population 
Gene Allele No Variant Reference 
Phase II enzymes 























































Q141K 919 0.01 16 




TYMS 1494del 799 0.44 16 
 









Two other phase 1 enzymes, CYP2A6 and CYP2B6, 
have been associated with efavirenz plasma concentra-
tion in HIV-infected patients. CYP2A6*9B and 
 
 





CYP2A6*17 have been identified as slow metaboliser 
variants.46,47 and have been reported at a frequency of 
5% and 12% respectively in Ghana (Table 1). CYP2B6 
c.516G>T mutation has also been associated with re-
duced enzyme activity and higher efavirenz concentra-
tion.48,49 This has also been detected in 45% of the 
Ghanaian population (Table 1). It was suggested by the 
authors that genotyping CYP2A6 and CYP2B6 en-
zymes may be useful in accurately predicting efavirenz 
concentration in HIV-infected patients which will en-
hance treatment. 
 
TPMT is one of the phase II enzymes that alter drug 
response in humans. TPMT*2, TPMT*3A and 
TPMT*3C are common variants associated with de-
creased enzyme activity.50 TPMT*3C was detected 
between 6.5% and 14.8% among the Ghanaian popula-
tion16, 41, 42 (Table 2). Patients who inherit two non-
functional TPMT alleles will accumulate excessive 
amounts of the metabolites and can suffer severe to 
fatal toxicity from drugs such as azathiopurine and 6-
mecaptopurine therapy. 
 
IMPLICATIONS FOR GHANA 
An ideal situation will be to genotype each individual 
for relevant genetic variants before treatment to max-
imise the outcome of therapeutics. However, due to 
financial constraints in developing countries such as 
Ghana, this option remains unfeasible at the moment. 
Allele frequency data from a national population can 
be used as an alternative for individual genotyping. 
Although this option may not be the best, it is the most 
practicable and technologically feasible option at the 
moment.  
 
Pharmacogenetic data can be used in a variety of ways. 
It can be used retrospectively to investigate ADRs or 
the basis of drug resistance. A polymorphic analysis of 
ADR cases or drug resistant cases can be compared 
with a population pharmacogenetic profile to determine 
if there are significant genetic differences between the 
ADR patients and the general population. Based on the 
results from such studies, drug dosages can be adjusted 
to achieve a better therapeutic outcome or the treatment 
plan for the patient changed. 
 
Knowledge of the genetic profile of a population can 
also be a useful guide in making National policy deci-
sions for example adding new drugs to the Essential 
Medicines List. New drugs can be evaluated in light of 
the scope and profile of the pharmacogenetic polymor-
phisms of the drug ADME genes. Treatment policy 
decisions can be made based on the potential risk of 
ADRs, therapeutic benefits of the drug and the availa-
bility of viable alternative treatments. 
 
Integrating pharmacogenetics data into patient man-
agement plan requires that all healthcare professionals 
(Doctors, Pharmacists, Nurses and laboratory techni-
cians) be familiar with the tests available, the interpre-
tation of pharmacogenetic data and be confident 
enough to use it. Currently healthcare professionals in 
Ghana and other health workers at the Ghana Health 
Service may not be aware of the availability of some 
these pharmacogenetic information on the Ghanaian 
population.  
 
THE WAY FORWARD 
The benefits of pharmacogenetics in individualising 
patient care has been shown, however, its deployment 
is beset with considerable challenges. In view of com-
peting demands in the healthcare, it is not easy to allo-
cate huge resources to this important field. The need to 
prioritise which drugs or disease areas would benefit 
most is important. Pharmacogenetics has the potential 
of providing opportunities for improving drug efficacy 
and safety. However, some areas of the world especial-
ly indigenous African populations have scarce infor-
mation in the current pharmacogenetics research(51, 52). 
There is the need to increase research in the area of 
pharmacogenetics for it to make a meaningful impact 
on genetically tailored treatment in Ghana. Each coun-
try has to determine their own national genotype data 
since it has been established that interethnic variations 
do exist and African populations do have relatively 
high genetic diversity. 
 
Training institutions of health professionals have to 
include pharmacogenetics in their curriculum at under-
graduate and post graduate levels. Pharmacogenetics 
can also be included in the continuous education pro-
grammes for Clinicians and Pharmacists who are al-
ready practicing. This will adequately equip these 
health professionals in public health, national formu-
lary decisions, applied genetics, medicine, pharmacy, 
and related disciplines on the need to integrate of ge-
netic information into public health decision making 
and provide guidelines for medical prioritization using 
pharmacogenetic information. 
 
To address some of these scarcity of allele frequency 
data on clinically relevant SNPs, International HapMap 
project (www.hapmap.org) and the Pharmacogenetics 
for Every Nation Initiative (www.pgeni.com) are set-













Ghana is one of the few countries in Africa whose 
population has been genotyped to some degree. How-
ever, there is the need to increase research in the area 
of pharmacogenetics. Available pharmacogenetic data 
has also not been compiled into a database for easy 
access by health professionals.  Relevant pharmaco-
genetic information available in Ghana has to be con-
sidered when making decisions for the national drug 
formulary.  
For healthcare professionals to appreciate the value of 
pharmacogenetic tests and interpretation of the results, 
all schools of Medicine and Pharmacy would have to 
integrate pharmacogenetics into their curriculum if not 
already present. Including a pharmacogenetics course 
in the continuing education of the health professionals 
already practicing will also help in creating pharmaco-
genetics awareness. Pharmacogenetics has made signif-
icant progress in the developed world. We in Ghana 
need to prepare to take advantage of the promises 
which the future holds for the country, doctors, phar-
macists and patients by maximising the benefits of 
drug use and experiencing fewer adverse events 
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